ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,804.50
0.14%
S&P ASX All Technology
3,082.20
0.46%
Brent Oil
82.425
-0.53%
US Dollar vs AUD
1.52296
0.35%
Bitcoin
62,081.49
-0.41%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Immunic Inc (IMUX)

  7. Immunic Inc (IMUX) News

IMUX

Immunic (IMUX)

Immunic Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IMUX
DateTimeSourceHeadlineSymbolCompany
08/05/202421:20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IMUXImmunic Inc
08/05/202420:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMUXImmunic Inc
08/05/202420:30PR Newswire (US)Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:IMUXImmunic Inc
06/05/202420:30PR Newswire (US)Immunic to Participate in Investor and Scientific Conferences in MayNASDAQ:IMUXImmunic Inc
01/05/202420:30PR Newswire (US)Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate UpdateNASDAQ:IMUXImmunic Inc
30/04/202420:30PR Newswire (US)Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & NeuroinflammationNASDAQ:IMUXImmunic Inc
04/04/202421:30PR Newswire (US)Immunic to Host MS R&D Day and Participate in Investor Conferences in AprilNASDAQ:IMUXImmunic Inc
20/03/202421:30PR Newswire (US)Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United StatesNASDAQ:IMUXImmunic Inc
09/03/202408:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMUXImmunic Inc
07/03/202422:30PR Newswire (US)Immunic to Participate in Investor and Scientific Conferences in MarchNASDAQ:IMUXImmunic Inc
07/03/202413:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMUXImmunic Inc
07/03/202413:51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMUXImmunic Inc
07/03/202413:51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMUXImmunic Inc
07/03/202413:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMUXImmunic Inc
07/03/202413:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMUXImmunic Inc
07/03/202413:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMUXImmunic Inc
29/02/202422:30PR Newswire (US)Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024NASDAQ:IMUXImmunic Inc
22/02/202422:38Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:IMUXImmunic Inc
22/02/202422:35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMUXImmunic Inc
22/02/202422:30PR Newswire (US)Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate UpdateNASDAQ:IMUXImmunic Inc
15/02/202422:30PR Newswire (US)Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate UpdateNASDAQ:IMUXImmunic Inc
15/02/202408:05Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:IMUXImmunic Inc
15/02/202400:47Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:IMUXImmunic Inc
14/02/202423:55Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:IMUXImmunic Inc
14/02/202408:36Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:IMUXImmunic Inc
06/02/202400:30Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:IMUXImmunic Inc
01/02/202422:30PR Newswire (US)Immunic to Participate in Investor and Scientific Conferences in FebruaryNASDAQ:IMUXImmunic Inc
25/01/202409:05Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:IMUXImmunic Inc
20/01/202408:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMUXImmunic Inc
20/01/202408:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMUXImmunic Inc
 Showing the most relevant articles for your search:NASDAQ:IMUX

Your Recent History

FX
AUDJPY
AUD vs Yen
NYSE
MRK
Merck
PM
XAUUSD
Gold vs US Dollar
COIN
ETHUSD
Ethereum
ASX
WDC
Westfield
ASX
SUN
Suncorp
ASX
XMM
S&P ASX 300 Metals and M...
ASX
XJO
S&P ASX 200
ASX
XAO
Australian SE All Ordina...
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NASDAQ
MSFT
Microsoft
ASX
TLS
Telstra
NYSE
NKE
Nike
NYSE
DIS
Walt Disney
ASX
CSL
CSL
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved